TrialThe Journal of infectious diseases2014

Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Mark S Sulkowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.